Metrics as of 10/17/2026, 08:37 AM (Berlin time), refresh in progress.
Kailera Therapeutics Stock
Kailera Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ronald C. Renaud Jr.
- Employees
- 145
- Market cap
- $1.5 B
- IPO
- 17/04/2026
Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in the US that specializes in developing therapies for obesity and related conditions. Founded in 2024 and headquartered in Waltham, Massachusetts, the company currently employs 145 employees. The product pipeline consists of various…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Kailera Therapeutics stock: price history
1D
-3.9%
1W
-3.1%
1M
-11.4%
6M
-56.7%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about Kailera Therapeutics
Analyst assessment of Kailera Therapeutics
PRICE TARGET LOW
US$36.00
CONSENSUS
US$42.00
MEDIAN
US$42.00
PRICE TARGET HIGH
US$48.00
No current analyst ratings available.
Kailera Therapeutics stock metrics
P/E
-6.39
P/B
1.03
EV/EBITDA
-6.84
RETURN ON EQUITY
-10.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.9%
FLOAT SHARES
89,386,334
AVG. DAILY VOLUME (30D)
1,340,773
Insider transactions (SEC)
Renaud Ronald C JR
Institutional holders
Comparable stocks
Frequently asked questions about Kailera Therapeutics stock
What does Kailera Therapeutics do?
Kailera Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ronald C. Renaud Jr., the company employs around 145 people.
The IPO was on 17/04/2026; the stock trades on NASDAQ under the ticker KLRA.
What do analysts say about Kailera Therapeutics stock?
The average price target is US$42.00, ranging from US$36.00 to US$48.00, with a median of US$42.00.
This is an external assessment, not a statement by Market Jury.
When does Kailera Therapeutics report next?
The next earnings date is 04/11/2026.
Does Kailera Therapeutics pay a dividend?
No, Kailera Therapeutics currently does not pay a dividend.
Which stocks are comparable to Kailera Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kailera Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kailera Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.